49. 全身性エリテマトーデス Systemic lupus erythematosus Clinical trials / Disease details


臨床試験数 : 993 薬物数 : 702 - (DrugBank : 184) / 標的遺伝子数 : 116 - 標的パスウェイ数 : 200

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05123586
(ClinicalTrials.gov)
March 7, 202216/11/2021A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus ErythematosusA Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Two-Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 as a Treatment for Adults With At Least Moderately Active Systemic Lupus ErythematosusSystemic Lupus ErythematosusDrug: LY3361237;Drug: PlaceboEli Lilly and CompanyNULLRecruiting18 Years65 YearsAll90Phase 2United States;Argentina;Czechia;France;Mexico;Poland;Puerto Rico;Taiwan;Russian Federation;Ukraine
2EUCTR2021-001406-30-PL
(EUCTR)
02/02/202212/01/2022A study investigating the treatment of Systemic Lupus Erythematosus with LY3361237A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Two Arm, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LY3361237 to Treat Adults with At Least Moderately Active Systemic Lupus Erythematosus Systemic Lupus Erythematosus (SLE)
MedDRA version: 21.1;Level: PT;Classification code 10042945;Term: Systemic lupus erythematosus;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: LY3361237
INN or Proposed INN: LY3361237
Other descriptive name: LY3361237
Eli Lilly and CompanyNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Phase 2United States;Czechia;Mexico;Puerto Rico;Argentina;Poland;Ukraine;Russian Federation
3NCT03933943
(ClinicalTrials.gov)
May 21, 201930/4/2019A Study of LY3361237 in Participants With Systemic Lupus ErythematosusA Phase 1, Randomized, Placebo-Controlled, Multiple- Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3361237 in Patients With Systemic Lupus ErythematosusLupus Erythematosus, SystemicDrug: LY3361237;Drug: PlaceboEli Lilly and CompanyNULLCompleted18 Years70 YearsAll28Phase 1United States